AUT00063

DRUG3 trials

Sponsors

Autifony Therapeutics Limited

Conditions

Age-Related Hearing LossHearing ImpairmentHearing LossTinnitus, Subjective

Phase 2

Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo

CompletedNCT02315508

Autifony Therapeutics LimitedTinnitus, Subjective

Start: 2014-10-31End: 2015-12-31Updated: 2016-03-31

Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss

CompletedNCT02345031

Autifony Therapeutics LimitedAge-Related Hearing Loss

Start: 2015-01-31End: 2016-06-30Updated: 2018-08-09

Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)

CompletedNCT02832128

Autifony Therapeutics LimitedHearing Impairment, Hearing Loss

Start: 2016-05-31End: 2017-04-30Updated: 2017-05-24

Related Papers

A balanced randomised placebo controlled blinded phase IIa multi-centre study to investigate the efficacy and safety of AUT00063 versus placebo in subjective tinnitus: The QUIET-1 trial.

2019-03-2715 citations